Tyra Biosciences, Inc. (TYRA)
28.65
+3.79
(+15.25%)
USD |
NASDAQ |
Sep 04, 16:00
28.70
+0.05
(+0.17%)
After-Hours: 20:00
Tyra Biosciences Debt to Equity Ratio : 0.0158 for June 30, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.0158 |
| March 31, 2026 | 0.0147 |
| December 31, 2025 | 0.0224 |
| September 30, 2025 | 0.0211 |
| June 30, 2025 | 0.0199 |
| March 31, 2025 | 0.0189 |
| December 31, 2024 | 0.0181 |
| September 30, 2024 | 0.0174 |
| June 30, 2024 | 0.017 |
| March 31, 2024 | 0.0166 |
| December 31, 2023 | 0.0318 |
| September 30, 2023 | 0.0275 |
| Date | Value |
|---|---|
| June 30, 2023 | 0.0254 |
| March 31, 2023 | 0.0104 |
| December 31, 2022 | 0.0102 |
| September 30, 2022 | 0.0099 |
| June 30, 2022 | 0.0096 |
| March 31, 2022 | 0.0093 |
| December 31, 2021 | 0.0039 |
| September 30, 2021 | 0.0038 |
| June 30, 2021 | |
| March 31, 2021 | -8.981 |
| December 31, 2020 | -2.038 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| CG Oncology, Inc. | 0.0086 |
| Arrowhead Pharmaceuticals, Inc. | 2.956 |
| Oncolytics Biotech, Inc. | -0.0726 |
| Sangamo Therapeutics, Inc. | -1.020 |
| Sarepta Therapeutics, Inc. | 0.6845 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 383.36M |
| Total Liabilities (Quarterly) | 29.70M |
| Shareholders Equity (Quarterly) | 353.66M |
| Current Ratio | 14.91 |
| Net Debt Paydown Yield | 0.01% |